Table of Contents Author Guidelines Submit a Manuscript
Disease Markers
Volume 28, Issue 1, Pages 1-14

Applicability of Antibody and mRNA Expression Microarrays for Identifying Diagnostic and Progression Markers of Early and Late Stage Colorectal Cancer

Sándor Spisák,1,2 Barnabás Galamb,1 Ferenc Sipos,1 Orsolya Galamb,1,2 Barnabás Wichmann,1 Norbert Solymosi,1 Balázs Nemes,3 Jeannette Molnár,4 Zsolt Tulassay,1,2 and Béla Molnár1,2

12nd Department of Medicine, Semmelweis University, Budapest, Hungary
2Molecular Medicine Research Unit, Hungarian Academy of Sciences, Budapest, Hungary
3Transplantation and Surgical Department, Semmelweis University, Budapest, Hungary
4Department of Nutrition, National Institute of Food and Nutritional Science, Budapest, Hungary

Received 12 February 2010; Accepted 12 February 2010

Copyright © 2010 Hindawi Publishing Corporation. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


The exact molecular background and the connection between protein and mRNA expression in colorectal cancer (CRC) development and progression are not completely elucidated. Our purposes were the identification of protein markers of colorectal carcinogenesis and progression using protein arrays and validation on tissue microarrays. The connection between antibody and mRNA expression array results was also examined. Using cancerous and adjacent normal samples from 10 patients with early and 6 with advanced CRC, 67 differentially expressed genes were identified between normal and cancerous samples. A marker set containing 6 proteins (CCNA1, AR, TOP1, TGFB, HSP60, ERK1) was developed which could differentiate normal specimen, early and late stage CRC with high sensitivity and specificity. Dukes D stage samples were analyzed on HGU133plus2.0 microarrays. In these samples, mRNA and protein expression of 143 genes showed strong positive correlations (R2 > 0.8), while a negative correlation (R2 > 0.9) was found in case of 95 genes. Based on our results a correlation could be established between transcriptome and antibody array results, hence the former may be used as a high-capacity screening method before applying antibody arrays containing already planned targets. Antibody microarrays may have a fundamental importance in testing of marker combinations and future application in diagnostics of tumorous diseases.